nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—endothelium—melanoma	0.0262	0.214	CbGeAlD
Epoprostenol—PTGIS—blood vessel—melanoma	0.0242	0.197	CbGeAlD
Epoprostenol—PTGIR—endothelium—melanoma	0.0151	0.123	CbGeAlD
Epoprostenol—PTGIR—blood vessel—melanoma	0.0139	0.113	CbGeAlD
Epoprostenol—PTGIS—mammalian vulva—melanoma	0.0102	0.0834	CbGeAlD
Epoprostenol—PTGIS—head—melanoma	0.00731	0.0596	CbGeAlD
Epoprostenol—PTGER1—head—melanoma	0.00679	0.0555	CbGeAlD
Epoprostenol—P2RY12—head—melanoma	0.00658	0.0537	CbGeAlD
Epoprostenol—PTGIS—lymph node—melanoma	0.00512	0.0418	CbGeAlD
Epoprostenol—PTGIR—head—melanoma	0.0042	0.0343	CbGeAlD
Epoprostenol—PTGIR—lymph node—melanoma	0.00294	0.024	CbGeAlD
Epoprostenol—Decreased appetite—Vemurafenib—melanoma	0.00176	0.00427	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00174	0.00424	CcSEcCtD
Epoprostenol—Fatigue—Vemurafenib—melanoma	0.00174	0.00424	CcSEcCtD
Epoprostenol—Haemoglobin—Bleomycin—melanoma	0.00173	0.00421	CcSEcCtD
Epoprostenol—Constipation—Vemurafenib—melanoma	0.00173	0.0042	CcSEcCtD
Epoprostenol—Pancytopenia—Temozolomide—melanoma	0.00172	0.0042	CcSEcCtD
Epoprostenol—Haemorrhage—Bleomycin—melanoma	0.00172	0.00419	CcSEcCtD
Epoprostenol—Hypoaesthesia—Bleomycin—melanoma	0.00171	0.00417	CcSEcCtD
Epoprostenol—Pulmonary oedema—Docetaxel—melanoma	0.00171	0.00417	CcSEcCtD
Epoprostenol—Pneumonia—Carmustine—melanoma	0.00168	0.0041	CcSEcCtD
Epoprostenol—Depression—Carmustine—melanoma	0.00167	0.00407	CcSEcCtD
Epoprostenol—Sepsis—Docetaxel—melanoma	0.00167	0.00406	CcSEcCtD
Epoprostenol—Weight decreased—Temozolomide—melanoma	0.00164	0.004	CcSEcCtD
Epoprostenol—Urinary tract infection—Carmustine—melanoma	0.00163	0.00396	CcSEcCtD
Epoprostenol—Pneumonia—Temozolomide—melanoma	0.00163	0.00396	CcSEcCtD
Epoprostenol—Infestation NOS—Temozolomide—melanoma	0.00162	0.00394	CcSEcCtD
Epoprostenol—Infestation—Temozolomide—melanoma	0.00162	0.00394	CcSEcCtD
Epoprostenol—Depression—Temozolomide—melanoma	0.00161	0.00393	CcSEcCtD
Epoprostenol—Flushing—Bleomycin—melanoma	0.0016	0.00389	CcSEcCtD
Epoprostenol—Body temperature increased—Vemurafenib—melanoma	0.0016	0.00389	CcSEcCtD
Epoprostenol—Pharyngitis—Dactinomycin—melanoma	0.00159	0.00388	CcSEcCtD
Epoprostenol—Urinary tract infection—Temozolomide—melanoma	0.00157	0.00383	CcSEcCtD
Epoprostenol—Hepatic failure—Docetaxel—melanoma	0.00155	0.00378	CcSEcCtD
Epoprostenol—Chills—Bleomycin—melanoma	0.00155	0.00376	CcSEcCtD
Epoprostenol—Sinusitis—Temozolomide—melanoma	0.00152	0.0037	CcSEcCtD
Epoprostenol—Haemoglobin—Carmustine—melanoma	0.00151	0.00368	CcSEcCtD
Epoprostenol—Haemorrhage—Carmustine—melanoma	0.0015	0.00366	CcSEcCtD
Epoprostenol—Hypoaesthesia—Carmustine—melanoma	0.0015	0.00364	CcSEcCtD
Epoprostenol—Flushing—Dactinomycin—melanoma	0.00149	0.00363	CcSEcCtD
Epoprostenol—Hypersensitivity—Vemurafenib—melanoma	0.00149	0.00362	CcSEcCtD
Epoprostenol—Oedema peripheral—Carmustine—melanoma	0.00148	0.00361	CcSEcCtD
Epoprostenol—Connective tissue disorder—Carmustine—melanoma	0.00148	0.0036	CcSEcCtD
Epoprostenol—Haemoglobin—Temozolomide—melanoma	0.00146	0.00355	CcSEcCtD
Epoprostenol—Haemorrhage—Temozolomide—melanoma	0.00145	0.00354	CcSEcCtD
Epoprostenol—Asthenia—Vemurafenib—melanoma	0.00145	0.00353	CcSEcCtD
Epoprostenol—Hypoaesthesia—Temozolomide—melanoma	0.00145	0.00352	CcSEcCtD
Epoprostenol—Pharyngitis—Temozolomide—melanoma	0.00144	0.00351	CcSEcCtD
Epoprostenol—Chills—Dactinomycin—melanoma	0.00144	0.00351	CcSEcCtD
Epoprostenol—Oedema peripheral—Temozolomide—melanoma	0.00143	0.00348	CcSEcCtD
Epoprostenol—Cardiac failure—Docetaxel—melanoma	0.00143	0.00348	CcSEcCtD
Epoprostenol—Pruritus—Vemurafenib—melanoma	0.00143	0.00348	CcSEcCtD
Epoprostenol—Connective tissue disorder—Temozolomide—melanoma	0.00143	0.00348	CcSEcCtD
Epoprostenol—Flushing—Carmustine—melanoma	0.0014	0.0034	CcSEcCtD
Epoprostenol—Anaemia—Bleomycin—melanoma	0.00139	0.00337	CcSEcCtD
Epoprostenol—Diarrhoea—Vemurafenib—melanoma	0.00138	0.00336	CcSEcCtD
Epoprostenol—Cardiac disorder—Temozolomide—melanoma	0.00135	0.00328	CcSEcCtD
Epoprostenol—Flushing—Temozolomide—melanoma	0.00135	0.00328	CcSEcCtD
Epoprostenol—Dizziness—Vemurafenib—melanoma	0.00134	0.00325	CcSEcCtD
Epoprostenol—Angiopathy—Temozolomide—melanoma	0.00132	0.00321	CcSEcCtD
Epoprostenol—Mental disorder—Carmustine—melanoma	0.00132	0.00321	CcSEcCtD
Epoprostenol—Mediastinal disorder—Temozolomide—melanoma	0.00131	0.00319	CcSEcCtD
Epoprostenol—Cough—Bleomycin—melanoma	0.00131	0.00318	CcSEcCtD
Epoprostenol—Chills—Temozolomide—melanoma	0.0013	0.00317	CcSEcCtD
Epoprostenol—Anaemia—Dactinomycin—melanoma	0.00129	0.00315	CcSEcCtD
Epoprostenol—Vomiting—Vemurafenib—melanoma	0.00128	0.00313	CcSEcCtD
Epoprostenol—Myalgia—Bleomycin—melanoma	0.00128	0.00311	CcSEcCtD
Epoprostenol—Chest pain—Bleomycin—melanoma	0.00128	0.00311	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Docetaxel—melanoma	0.00128	0.00311	CcSEcCtD
Epoprostenol—Rash—Vemurafenib—melanoma	0.00127	0.0031	CcSEcCtD
Epoprostenol—Mental disorder—Temozolomide—melanoma	0.00127	0.0031	CcSEcCtD
Epoprostenol—Dermatitis—Vemurafenib—melanoma	0.00127	0.0031	CcSEcCtD
Epoprostenol—Back pain—Carmustine—melanoma	0.00127	0.00308	CcSEcCtD
Epoprostenol—Headache—Vemurafenib—melanoma	0.00127	0.00308	CcSEcCtD
Epoprostenol—Confusional state—Bleomycin—melanoma	0.00123	0.003	CcSEcCtD
Epoprostenol—Tremor—Carmustine—melanoma	0.00123	0.00298	CcSEcCtD
Epoprostenol—Oedema—Bleomycin—melanoma	0.00122	0.00298	CcSEcCtD
Epoprostenol—Anaphylactic shock—Bleomycin—melanoma	0.00122	0.00298	CcSEcCtD
Epoprostenol—Back pain—Temozolomide—melanoma	0.00122	0.00298	CcSEcCtD
Epoprostenol—Infection—Bleomycin—melanoma	0.00122	0.00296	CcSEcCtD
Epoprostenol—Anaemia—Carmustine—melanoma	0.00121	0.00294	CcSEcCtD
Epoprostenol—Agitation—Carmustine—melanoma	0.0012	0.00293	CcSEcCtD
Epoprostenol—Nausea—Vemurafenib—melanoma	0.0012	0.00292	CcSEcCtD
Epoprostenol—Thrombocytopenia—Bleomycin—melanoma	0.0012	0.00292	CcSEcCtD
Epoprostenol—Myalgia—Dactinomycin—melanoma	0.00119	0.0029	CcSEcCtD
Epoprostenol—Tremor—Temozolomide—melanoma	0.00119	0.00288	CcSEcCtD
Epoprostenol—Anaemia—Temozolomide—melanoma	0.00117	0.00285	CcSEcCtD
Epoprostenol—Anorexia—Bleomycin—melanoma	0.00117	0.00284	CcSEcCtD
Epoprostenol—Agitation—Temozolomide—melanoma	0.00116	0.00283	CcSEcCtD
Epoprostenol—Pancytopenia—Docetaxel—melanoma	0.00115	0.00279	CcSEcCtD
Epoprostenol—Hypotension—Bleomycin—melanoma	0.00114	0.00278	CcSEcCtD
Epoprostenol—Oedema—Dactinomycin—melanoma	0.00114	0.00278	CcSEcCtD
Epoprostenol—Infection—Dactinomycin—melanoma	0.00113	0.00276	CcSEcCtD
Epoprostenol—Palpitations—Temozolomide—melanoma	0.00112	0.00272	CcSEcCtD
Epoprostenol—Thrombocytopenia—Dactinomycin—melanoma	0.00112	0.00272	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Bleomycin—melanoma	0.00112	0.00271	CcSEcCtD
Epoprostenol—Chest pain—Carmustine—melanoma	0.00111	0.00271	CcSEcCtD
Epoprostenol—Myalgia—Carmustine—melanoma	0.00111	0.00271	CcSEcCtD
Epoprostenol—Anxiety—Carmustine—melanoma	0.00111	0.0027	CcSEcCtD
Epoprostenol—Cough—Temozolomide—melanoma	0.0011	0.00269	CcSEcCtD
Epoprostenol—Paraesthesia—Bleomycin—melanoma	0.0011	0.00267	CcSEcCtD
Epoprostenol—Weight decreased—Docetaxel—melanoma	0.00109	0.00266	CcSEcCtD
Epoprostenol—Dyspnoea—Bleomycin—melanoma	0.00109	0.00266	CcSEcCtD
Epoprostenol—Anorexia—Dactinomycin—melanoma	0.00109	0.00265	CcSEcCtD
Epoprostenol—Pneumonia—Docetaxel—melanoma	0.00108	0.00264	CcSEcCtD
Epoprostenol—Confusional state—Carmustine—melanoma	0.00108	0.00262	CcSEcCtD
Epoprostenol—Myalgia—Temozolomide—melanoma	0.00108	0.00262	CcSEcCtD
Epoprostenol—Arthralgia—Temozolomide—melanoma	0.00108	0.00262	CcSEcCtD
Epoprostenol—Infestation NOS—Docetaxel—melanoma	0.00108	0.00262	CcSEcCtD
Epoprostenol—Infestation—Docetaxel—melanoma	0.00108	0.00262	CcSEcCtD
Epoprostenol—Anxiety—Temozolomide—melanoma	0.00107	0.00261	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00107	0.0026	CcSEcCtD
Epoprostenol—Oedema—Carmustine—melanoma	0.00107	0.0026	CcSEcCtD
Epoprostenol—Decreased appetite—Bleomycin—melanoma	0.00106	0.00259	CcSEcCtD
Epoprostenol—Infection—Carmustine—melanoma	0.00106	0.00258	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Docetaxel—melanoma	0.00106	0.00258	CcSEcCtD
Epoprostenol—Myocardial infarction—Docetaxel—melanoma	0.00106	0.00257	CcSEcCtD
Epoprostenol—Dry mouth—Temozolomide—melanoma	0.00105	0.00256	CcSEcCtD
Epoprostenol—Pain—Bleomycin—melanoma	0.00105	0.00255	CcSEcCtD
Epoprostenol—Thrombocytopenia—Carmustine—melanoma	0.00105	0.00255	CcSEcCtD
Epoprostenol—Tachycardia—Carmustine—melanoma	0.00104	0.00254	CcSEcCtD
Epoprostenol—Confusional state—Temozolomide—melanoma	0.00104	0.00253	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00104	0.00253	CcSEcCtD
Epoprostenol—Oedema—Temozolomide—melanoma	0.00103	0.00251	CcSEcCtD
Epoprostenol—Anaphylactic shock—Temozolomide—melanoma	0.00103	0.00251	CcSEcCtD
Epoprostenol—Infection—Temozolomide—melanoma	0.00103	0.0025	CcSEcCtD
Epoprostenol—Anorexia—Carmustine—melanoma	0.00102	0.00248	CcSEcCtD
Epoprostenol—Epistaxis—Docetaxel—melanoma	0.00102	0.00247	CcSEcCtD
Epoprostenol—Nervous system disorder—Temozolomide—melanoma	0.00101	0.00246	CcSEcCtD
Epoprostenol—Thrombocytopenia—Temozolomide—melanoma	0.00101	0.00246	CcSEcCtD
Epoprostenol—Skin disorder—Temozolomide—melanoma	0.001	0.00244	CcSEcCtD
Epoprostenol—Hypotension—Carmustine—melanoma	0.000998	0.00243	CcSEcCtD
Epoprostenol—Hyperhidrosis—Temozolomide—melanoma	0.000998	0.00243	CcSEcCtD
Epoprostenol—Decreased appetite—Dactinomycin—melanoma	0.000992	0.00242	CcSEcCtD
Epoprostenol—Fatigue—Dactinomycin—melanoma	0.000984	0.0024	CcSEcCtD
Epoprostenol—Anorexia—Temozolomide—melanoma	0.000984	0.0024	CcSEcCtD
Epoprostenol—Pain—Dactinomycin—melanoma	0.000976	0.00238	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Carmustine—melanoma	0.000973	0.00237	CcSEcCtD
Epoprostenol—Urticaria—Bleomycin—melanoma	0.000972	0.00237	CcSEcCtD
Epoprostenol—Haemoglobin—Docetaxel—melanoma	0.000971	0.00236	CcSEcCtD
Epoprostenol—Rhinitis—Docetaxel—melanoma	0.000969	0.00236	CcSEcCtD
Epoprostenol—Body temperature increased—Bleomycin—melanoma	0.000968	0.00235	CcSEcCtD
Epoprostenol—Haemorrhage—Docetaxel—melanoma	0.000966	0.00235	CcSEcCtD
Epoprostenol—Insomnia—Carmustine—melanoma	0.000966	0.00235	CcSEcCtD
Epoprostenol—Hypoaesthesia—Docetaxel—melanoma	0.000962	0.00234	CcSEcCtD
Epoprostenol—Paraesthesia—Carmustine—melanoma	0.000959	0.00233	CcSEcCtD
Epoprostenol—Pharyngitis—Docetaxel—melanoma	0.000959	0.00233	CcSEcCtD
Epoprostenol—Dyspnoea—Carmustine—melanoma	0.000953	0.00232	CcSEcCtD
Epoprostenol—Oedema peripheral—Docetaxel—melanoma	0.000952	0.00232	CcSEcCtD
Epoprostenol—Somnolence—Carmustine—melanoma	0.00095	0.00231	CcSEcCtD
Epoprostenol—Connective tissue disorder—Docetaxel—melanoma	0.00095	0.00231	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Temozolomide—melanoma	0.000941	0.00229	CcSEcCtD
Epoprostenol—Insomnia—Temozolomide—melanoma	0.000934	0.00227	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Dactinomycin—melanoma	0.000933	0.00227	CcSEcCtD
Epoprostenol—Decreased appetite—Carmustine—melanoma	0.000929	0.00226	CcSEcCtD
Epoprostenol—Paraesthesia—Temozolomide—melanoma	0.000927	0.00226	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Carmustine—melanoma	0.000922	0.00224	CcSEcCtD
Epoprostenol—Dyspnoea—Temozolomide—melanoma	0.000921	0.00224	CcSEcCtD
Epoprostenol—Somnolence—Temozolomide—melanoma	0.000918	0.00223	CcSEcCtD
Epoprostenol—Constipation—Carmustine—melanoma	0.000914	0.00222	CcSEcCtD
Epoprostenol—Pain—Carmustine—melanoma	0.000914	0.00222	CcSEcCtD
Epoprostenol—Dyspepsia—Temozolomide—melanoma	0.000909	0.00221	CcSEcCtD
Epoprostenol—Abdominal pain—Dactinomycin—melanoma	0.000902	0.0022	CcSEcCtD
Epoprostenol—Body temperature increased—Dactinomycin—melanoma	0.000902	0.0022	CcSEcCtD
Epoprostenol—Hypersensitivity—Bleomycin—melanoma	0.000902	0.00219	CcSEcCtD
Epoprostenol—Decreased appetite—Temozolomide—melanoma	0.000898	0.00218	CcSEcCtD
Epoprostenol—Flushing—Docetaxel—melanoma	0.000897	0.00218	CcSEcCtD
Epoprostenol—Cardiac disorder—Docetaxel—melanoma	0.000897	0.00218	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Temozolomide—melanoma	0.000891	0.00217	CcSEcCtD
Epoprostenol—Fatigue—Temozolomide—melanoma	0.00089	0.00217	CcSEcCtD
Epoprostenol—Pain—Temozolomide—melanoma	0.000883	0.00215	CcSEcCtD
Epoprostenol—Constipation—Temozolomide—melanoma	0.000883	0.00215	CcSEcCtD
Epoprostenol—Asthenia—Bleomycin—melanoma	0.000878	0.00214	CcSEcCtD
Epoprostenol—Angiopathy—Docetaxel—melanoma	0.000877	0.00213	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Carmustine—melanoma	0.000874	0.00213	CcSEcCtD
Epoprostenol—Mediastinal disorder—Docetaxel—melanoma	0.000871	0.00212	CcSEcCtD
Epoprostenol—Chills—Docetaxel—melanoma	0.000867	0.00211	CcSEcCtD
Epoprostenol—Pruritus—Bleomycin—melanoma	0.000866	0.00211	CcSEcCtD
Epoprostenol—Mental disorder—Docetaxel—melanoma	0.000847	0.00206	CcSEcCtD
Epoprostenol—Abdominal pain—Carmustine—melanoma	0.000845	0.00206	CcSEcCtD
Epoprostenol—Body temperature increased—Carmustine—melanoma	0.000845	0.00206	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Temozolomide—melanoma	0.000844	0.00205	CcSEcCtD
Epoprostenol—Hypersensitivity—Dactinomycin—melanoma	0.000841	0.00205	CcSEcCtD
Epoprostenol—Urticaria—Temozolomide—melanoma	0.00082	0.002	CcSEcCtD
Epoprostenol—Asthenia—Dactinomycin—melanoma	0.000819	0.00199	CcSEcCtD
Epoprostenol—Abdominal pain—Temozolomide—melanoma	0.000816	0.00199	CcSEcCtD
Epoprostenol—Body temperature increased—Temozolomide—melanoma	0.000816	0.00199	CcSEcCtD
Epoprostenol—Back pain—Docetaxel—melanoma	0.000814	0.00198	CcSEcCtD
Epoprostenol—Muscle spasms—Docetaxel—melanoma	0.000809	0.00197	CcSEcCtD
Epoprostenol—Hypersensitivity—Carmustine—melanoma	0.000787	0.00192	CcSEcCtD
Epoprostenol—Diarrhoea—Dactinomycin—melanoma	0.000781	0.0019	CcSEcCtD
Epoprostenol—Vomiting—Bleomycin—melanoma	0.000778	0.00189	CcSEcCtD
Epoprostenol—Anaemia—Docetaxel—melanoma	0.000778	0.00189	CcSEcCtD
Epoprostenol—Rash—Bleomycin—melanoma	0.000772	0.00188	CcSEcCtD
Epoprostenol—Dermatitis—Bleomycin—melanoma	0.000771	0.00188	CcSEcCtD
Epoprostenol—Asthenia—Carmustine—melanoma	0.000767	0.00187	CcSEcCtD
Epoprostenol—Hypersensitivity—Temozolomide—melanoma	0.000761	0.00185	CcSEcCtD
Epoprostenol—Syncope—Docetaxel—melanoma	0.000754	0.00184	CcSEcCtD
Epoprostenol—Palpitations—Docetaxel—melanoma	0.000743	0.00181	CcSEcCtD
Epoprostenol—Asthenia—Temozolomide—melanoma	0.000741	0.0018	CcSEcCtD
Epoprostenol—Loss of consciousness—Docetaxel—melanoma	0.000739	0.0018	CcSEcCtD
Epoprostenol—Cough—Docetaxel—melanoma	0.000734	0.00179	CcSEcCtD
Epoprostenol—Diarrhoea—Carmustine—melanoma	0.000731	0.00178	CcSEcCtD
Epoprostenol—Pruritus—Temozolomide—melanoma	0.00073	0.00178	CcSEcCtD
Epoprostenol—Nausea—Bleomycin—melanoma	0.000727	0.00177	CcSEcCtD
Epoprostenol—Vomiting—Dactinomycin—melanoma	0.000726	0.00177	CcSEcCtD
Epoprostenol—Rash—Dactinomycin—melanoma	0.00072	0.00175	CcSEcCtD
Epoprostenol—Chest pain—Docetaxel—melanoma	0.000716	0.00174	CcSEcCtD
Epoprostenol—Myalgia—Docetaxel—melanoma	0.000716	0.00174	CcSEcCtD
Epoprostenol—Arthralgia—Docetaxel—melanoma	0.000716	0.00174	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000711	0.00173	CcSEcCtD
Epoprostenol—Dizziness—Carmustine—melanoma	0.000707	0.00172	CcSEcCtD
Epoprostenol—Diarrhoea—Temozolomide—melanoma	0.000706	0.00172	CcSEcCtD
Epoprostenol—Dry mouth—Docetaxel—melanoma	0.0007	0.0017	CcSEcCtD
Epoprostenol—Confusional state—Docetaxel—melanoma	0.000692	0.00168	CcSEcCtD
Epoprostenol—Oedema—Docetaxel—melanoma	0.000687	0.00167	CcSEcCtD
Epoprostenol—Anaphylactic shock—Docetaxel—melanoma	0.000687	0.00167	CcSEcCtD
Epoprostenol—Dizziness—Temozolomide—melanoma	0.000683	0.00166	CcSEcCtD
Epoprostenol—Infection—Docetaxel—melanoma	0.000682	0.00166	CcSEcCtD
Epoprostenol—Vomiting—Carmustine—melanoma	0.000679	0.00165	CcSEcCtD
Epoprostenol—Nausea—Dactinomycin—melanoma	0.000678	0.00165	CcSEcCtD
Epoprostenol—Shock—Docetaxel—melanoma	0.000676	0.00164	CcSEcCtD
Epoprostenol—Rash—Carmustine—melanoma	0.000674	0.00164	CcSEcCtD
Epoprostenol—Nervous system disorder—Docetaxel—melanoma	0.000673	0.00164	CcSEcCtD
Epoprostenol—Dermatitis—Carmustine—melanoma	0.000673	0.00164	CcSEcCtD
Epoprostenol—Thrombocytopenia—Docetaxel—melanoma	0.000672	0.00164	CcSEcCtD
Epoprostenol—Tachycardia—Docetaxel—melanoma	0.00067	0.00163	CcSEcCtD
Epoprostenol—Headache—Carmustine—melanoma	0.000669	0.00163	CcSEcCtD
Epoprostenol—Skin disorder—Docetaxel—melanoma	0.000667	0.00162	CcSEcCtD
Epoprostenol—Vomiting—Temozolomide—melanoma	0.000656	0.0016	CcSEcCtD
Epoprostenol—Anorexia—Docetaxel—melanoma	0.000654	0.00159	CcSEcCtD
Epoprostenol—Rash—Temozolomide—melanoma	0.000651	0.00158	CcSEcCtD
Epoprostenol—Dermatitis—Temozolomide—melanoma	0.00065	0.00158	CcSEcCtD
Epoprostenol—Headache—Temozolomide—melanoma	0.000647	0.00157	CcSEcCtD
Epoprostenol—Hypotension—Docetaxel—melanoma	0.000642	0.00156	CcSEcCtD
Epoprostenol—Nausea—Carmustine—melanoma	0.000635	0.00154	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Docetaxel—melanoma	0.000626	0.00152	CcSEcCtD
Epoprostenol—Insomnia—Docetaxel—melanoma	0.000621	0.00151	CcSEcCtD
Epoprostenol—Paraesthesia—Docetaxel—melanoma	0.000617	0.0015	CcSEcCtD
Epoprostenol—Nausea—Temozolomide—melanoma	0.000613	0.00149	CcSEcCtD
Epoprostenol—Dyspnoea—Docetaxel—melanoma	0.000612	0.00149	CcSEcCtD
Epoprostenol—Somnolence—Docetaxel—melanoma	0.00061	0.00149	CcSEcCtD
Epoprostenol—Dyspepsia—Docetaxel—melanoma	0.000604	0.00147	CcSEcCtD
Epoprostenol—Decreased appetite—Docetaxel—melanoma	0.000597	0.00145	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Docetaxel—melanoma	0.000593	0.00144	CcSEcCtD
Epoprostenol—Fatigue—Docetaxel—melanoma	0.000592	0.00144	CcSEcCtD
Epoprostenol—Pain—Docetaxel—melanoma	0.000587	0.00143	CcSEcCtD
Epoprostenol—Constipation—Docetaxel—melanoma	0.000587	0.00143	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Docetaxel—melanoma	0.000561	0.00137	CcSEcCtD
Epoprostenol—Abdominal pain—Docetaxel—melanoma	0.000543	0.00132	CcSEcCtD
Epoprostenol—Body temperature increased—Docetaxel—melanoma	0.000543	0.00132	CcSEcCtD
Epoprostenol—Hypersensitivity—Docetaxel—melanoma	0.000506	0.00123	CcSEcCtD
Epoprostenol—Asthenia—Docetaxel—melanoma	0.000493	0.0012	CcSEcCtD
Epoprostenol—Pruritus—Docetaxel—melanoma	0.000486	0.00118	CcSEcCtD
Epoprostenol—Diarrhoea—Docetaxel—melanoma	0.00047	0.00114	CcSEcCtD
Epoprostenol—Dizziness—Docetaxel—melanoma	0.000454	0.00111	CcSEcCtD
Epoprostenol—Vomiting—Docetaxel—melanoma	0.000437	0.00106	CcSEcCtD
Epoprostenol—Rash—Docetaxel—melanoma	0.000433	0.00105	CcSEcCtD
Epoprostenol—Dermatitis—Docetaxel—melanoma	0.000433	0.00105	CcSEcCtD
Epoprostenol—Headache—Docetaxel—melanoma	0.00043	0.00105	CcSEcCtD
Epoprostenol—Nausea—Docetaxel—melanoma	0.000408	0.000993	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—FGF1—melanoma	9.6e-05	0.000206	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CSF2—melanoma	9.6e-05	0.000206	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CSF2—melanoma	9.6e-05	0.000206	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGF1—melanoma	9.6e-05	0.000206	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—melanoma	9.55e-05	0.000205	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—melanoma	9.45e-05	0.000203	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—melanoma	9.45e-05	0.000203	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—E2F1—melanoma	9.39e-05	0.000201	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—E2F1—melanoma	9.39e-05	0.000201	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CB—melanoma	9.35e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CB—melanoma	9.35e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1A—melanoma	9.33e-05	0.0002	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—melanoma	9.33e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—melanoma	9.31e-05	0.0002	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PDGFRA—melanoma	9.29e-05	0.000199	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PDGFRA—melanoma	9.29e-05	0.000199	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—melanoma	9.29e-05	0.000199	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RAC1—melanoma	9.27e-05	0.000199	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ITGB3—melanoma	9.2e-05	0.000197	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ITGB3—melanoma	9.2e-05	0.000197	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PRKCA—melanoma	9.2e-05	0.000197	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PRKCA—melanoma	9.2e-05	0.000197	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—melanoma	9.19e-05	0.000197	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SPP1—melanoma	9.02e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SPP1—melanoma	9.02e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CB—melanoma	9.02e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAP2K2—melanoma	8.99e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAP2K2—melanoma	8.99e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—melanoma	8.98e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—melanoma	8.98e-05	0.000193	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—melanoma	8.94e-05	0.000192	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—melanoma	8.89e-05	0.000191	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—melanoma	8.81e-05	0.000189	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—melanoma	8.59e-05	0.000184	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—melanoma	8.59e-05	0.000184	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—melanoma	8.55e-05	0.000183	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—melanoma	8.55e-05	0.000183	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	8.55e-05	0.000183	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RAC1—melanoma	8.53e-05	0.000183	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RAC1—melanoma	8.53e-05	0.000183	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KDR—melanoma	8.5e-05	0.000182	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—melanoma	8.33e-05	0.000178	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—melanoma	8.31e-05	0.000178	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FN1—melanoma	8.18e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—melanoma	8.18e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—melanoma	8.18e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—melanoma	8.11e-05	0.000174	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLCB4—melanoma	8.05e-05	0.000173	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOTCH1—melanoma	8.01e-05	0.000172	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK3—melanoma	7.95e-05	0.00017	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—FASN—melanoma	7.9e-05	0.000169	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CD80—melanoma	7.85e-05	0.000168	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APC—melanoma	7.83e-05	0.000168	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KIT—melanoma	7.83e-05	0.000168	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CG—melanoma	7.83e-05	0.000168	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—melanoma	7.83e-05	0.000168	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—melanoma	7.82e-05	0.000168	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—melanoma	7.82e-05	0.000168	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—melanoma	7.8e-05	0.000167	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGF—melanoma	7.74e-05	0.000166	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—melanoma	7.74e-05	0.000166	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIP4K2A—melanoma	7.57e-05	0.000162	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC6A11—melanoma	7.57e-05	0.000162	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK1—melanoma	7.57e-05	0.000162	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—melanoma	7.57e-05	0.000162	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FN1—melanoma	7.53e-05	0.000161	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FN1—melanoma	7.53e-05	0.000161	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK3—melanoma	7.5e-05	0.000161	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOTCH1—melanoma	7.37e-05	0.000158	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOTCH1—melanoma	7.37e-05	0.000158	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTAP—melanoma	7.36e-05	0.000158	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—melanoma	7.36e-05	0.000158	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CD80—melanoma	7.22e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CD80—melanoma	7.22e-05	0.000155	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KIT—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KIT—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—melanoma	7.21e-05	0.000154	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	7.2e-05	0.000154	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—melanoma	7.17e-05	0.000154	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—melanoma	7.15e-05	0.000153	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK1—melanoma	7.14e-05	0.000153	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—melanoma	7.13e-05	0.000153	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGF—melanoma	7.12e-05	0.000153	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGF—melanoma	7.12e-05	0.000153	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAP2K1—melanoma	6.93e-05	0.000149	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK3—melanoma	6.9e-05	0.000148	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK3—melanoma	6.9e-05	0.000148	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CD—melanoma	6.88e-05	0.000148	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—melanoma	6.82e-05	0.000146	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—melanoma	6.77e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—melanoma	6.77e-05	0.000145	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—melanoma	6.74e-05	0.000144	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—melanoma	6.6e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—melanoma	6.6e-05	0.000141	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGF2—melanoma	6.59e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—melanoma	6.57e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK1—melanoma	6.57e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK1—melanoma	6.57e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—melanoma	6.57e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—melanoma	6.57e-05	0.000141	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PHGDH—melanoma	6.56e-05	0.000141	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LUM—melanoma	6.56e-05	0.000141	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPSE—melanoma	6.44e-05	0.000138	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAP2K1—melanoma	6.38e-05	0.000137	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAP2K1—melanoma	6.38e-05	0.000137	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CD—melanoma	6.34e-05	0.000136	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CD—melanoma	6.34e-05	0.000136	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CUBN—melanoma	6.32e-05	0.000135	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—melanoma	6.28e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—melanoma	6.28e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—melanoma	6.2e-05	0.000133	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—melanoma	6.2e-05	0.000133	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—melanoma	6.19e-05	0.000133	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MDM2—melanoma	6.17e-05	0.000132	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SDHD—melanoma	6.1e-05	0.000131	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BSG—melanoma	6.1e-05	0.000131	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CSPG4—melanoma	6.1e-05	0.000131	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—melanoma	6.08e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—melanoma	6.08e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGF2—melanoma	6.07e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGF2—melanoma	6.07e-05	0.00013	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CB—melanoma	6e-05	0.000129	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPAM—melanoma	5.91e-05	0.000127	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—melanoma	5.82e-05	0.000125	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—melanoma	5.77e-05	0.000124	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—melanoma	5.73e-05	0.000123	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—melanoma	5.7e-05	0.000122	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—melanoma	5.7e-05	0.000122	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MDM2—melanoma	5.68e-05	0.000122	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MDM2—melanoma	5.68e-05	0.000122	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—melanoma	5.63e-05	0.000121	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—melanoma	5.6e-05	0.00012	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—melanoma	5.6e-05	0.00012	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—melanoma	5.57e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CB—melanoma	5.52e-05	0.000118	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CB—melanoma	5.52e-05	0.000118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—melanoma	5.52e-05	0.000118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—melanoma	5.51e-05	0.000118	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—melanoma	5.5e-05	0.000118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—melanoma	5.48e-05	0.000118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—melanoma	5.37e-05	0.000115	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—melanoma	5.37e-05	0.000115	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—melanoma	5.32e-05	0.000114	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—melanoma	5.31e-05	0.000114	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—melanoma	5.31e-05	0.000114	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—melanoma	5.27e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—melanoma	5.27e-05	0.000113	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—melanoma	5.22e-05	0.000112	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—melanoma	5.2e-05	0.000111	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—melanoma	5.19e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—melanoma	5.18e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—melanoma	5.18e-05	0.000111	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFKB1—melanoma	5.16e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—melanoma	5.13e-05	0.00011	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—melanoma	5.13e-05	0.00011	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—melanoma	5.08e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—melanoma	5.08e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—melanoma	5.07e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—melanoma	5.07e-05	0.000109	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—melanoma	5.06e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—melanoma	5.05e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—melanoma	5.05e-05	0.000108	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PLA2G6—melanoma	5.02e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—melanoma	4.94e-05	0.000106	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—melanoma	4.94e-05	0.000106	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—melanoma	4.9e-05	0.000105	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—melanoma	4.9e-05	0.000105	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—melanoma	4.8e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—melanoma	4.8e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—melanoma	4.78e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—melanoma	4.78e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—melanoma	4.77e-05	0.000102	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—melanoma	4.77e-05	0.000102	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKB1—melanoma	4.75e-05	0.000102	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKB1—melanoma	4.75e-05	0.000102	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—melanoma	4.68e-05	0.0001	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—melanoma	4.66e-05	9.98e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—melanoma	4.66e-05	9.98e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—melanoma	4.64e-05	9.94e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—melanoma	4.63e-05	9.91e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—VCAN—melanoma	4.51e-05	9.67e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—melanoma	4.49e-05	9.63e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK3—melanoma	4.43e-05	9.49e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—melanoma	4.31e-05	9.24e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—melanoma	4.31e-05	9.24e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—melanoma	4.31e-05	9.23e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	4.27e-05	9.16e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—melanoma	4.27e-05	9.15e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—melanoma	4.27e-05	9.15e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—melanoma	4.26e-05	9.12e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—melanoma	4.26e-05	9.12e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK1—melanoma	4.22e-05	9.03e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—melanoma	4.21e-05	9.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	4.12e-05	8.84e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK3—melanoma	4.08e-05	8.74e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK3—melanoma	4.08e-05	8.74e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—melanoma	3.98e-05	8.53e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—melanoma	3.97e-05	8.5e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—melanoma	3.97e-05	8.5e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK1—melanoma	3.88e-05	8.31e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK1—melanoma	3.88e-05	8.31e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—melanoma	3.88e-05	8.31e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—melanoma	3.88e-05	8.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP17A1—melanoma	3.81e-05	8.16e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	3.76e-05	8.05e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	3.71e-05	7.95e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—melanoma	3.66e-05	7.85e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—melanoma	3.66e-05	7.85e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—melanoma	3.66e-05	7.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNA11—melanoma	3.6e-05	7.71e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—melanoma	3.54e-05	7.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FASN—melanoma	3.52e-05	7.54e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A5—melanoma	3.46e-05	7.42e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—melanoma	3.38e-05	7.25e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—melanoma	3.37e-05	7.21e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—melanoma	3.37e-05	7.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CD44—melanoma	3.34e-05	7.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNAQ—melanoma	3.34e-05	7.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.27e-05	7.02e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—melanoma	3.26e-05	6.98e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—melanoma	3.26e-05	6.98e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.24e-05	6.95e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—melanoma	3.24e-05	6.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1B1—melanoma	3.21e-05	6.87e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—melanoma	3.11e-05	6.68e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—melanoma	3.11e-05	6.68e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—melanoma	2.99e-05	6.4e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—melanoma	2.98e-05	6.39e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—melanoma	2.98e-05	6.39e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.83e-05	6.06e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—melanoma	2.75e-05	5.89e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—melanoma	2.75e-05	5.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—melanoma	2.64e-05	5.66e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PRKCA—melanoma	2.43e-05	5.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ERCC2—melanoma	2.41e-05	5.16e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2e-05	4.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—melanoma	1.9e-05	4.08e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—melanoma	1.84e-05	3.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CD—melanoma	1.67e-05	3.58e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—melanoma	1.65e-05	3.54e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CB—melanoma	1.46e-05	3.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—melanoma	1.44e-05	3.1e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—melanoma	1.26e-05	2.7e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—melanoma	8.89e-06	1.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—melanoma	7.26e-06	1.56e-05	CbGpPWpGaD
